Cellectar Biosciences Inc (CLRB) concluded trading on Wednesday at a closing price of $0.25, with 4.34 million shares of worth about $1.08 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -91.11% during that period and on December 18, 2024 the price saw a loss of about -5.11%. Currently the company’s common shares owned by public are about 40.57M shares, out of which, 40.04M shares are available for trading.
Stock saw a price change of -18.41% in past 5 days and over the past one month there was a price change of -85.93%. Year-to-date (YTD), CLRB shares are showing a performance of -91.01% which decreased to -90.16% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.23 but also hit the highest price of $4.45 during that period. The average intraday trading volume for Cellectar Biosciences Inc shares is 1.38 million. The stock is currently trading -77.72% below its 20-day simple moving average (SMA20), while that difference is down -85.10% for SMA50 and it goes to -90.09% lower than SMA200.
Cellectar Biosciences Inc (NASDAQ: CLRB) currently have 40.57M outstanding shares and institutions hold larger chunk of about 34.01% of that.
The stock has a current market capitalization of $10.28M and its 3Y-monthly beta is at 0.92. It has posted earnings per share of -$1.87 in the same period. It has Quick Ratio of 1.77 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CLRB, volatility over the week remained 16.00% while standing at 11.75% over the month.
Stock’s fiscal year EPS is expected to rise by 49.60% while it is estimated to increase by 53.59% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Ladenburg Thalmann on December 05, 2024 offering a Buy rating for the stock and assigned a target price of $13 to it. Stock get a Buy rating from Ladenburg Thalmann on December 21, 2016.
